Alert Header goes here

Rutland Regional Medical Center

Be sure the class of "ShowPanel" is added to the div of "AlertPanel" or the panel will not show.

An image can be added. Be sure to add the class of "Left" or "Right" if the text should flow around it.

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Itaque hic eos quasi nisi adipisci voluptas maxime placeat atque fugiat doloremque sint modi necessitatibus ea impedit laborum, distinctio, totam, quo nihil.

Skip to Content

Breast-Adjuvant Therapy Comparing Chemotherapy Alone to Chemotherapy Plus Trastuzumab


NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

To determine whether the addition of the drug trastuzumab (Herceptin) to chemotherapy improves invasive disease-free survival in women with resected node-positive or high-risk node negative breast cancer with reported HER-2 low by all HER 2 testing performed

National Surgical Adjuvant Breast and Bowel Project, an NCI Cooperative Group
Rebecca Denofer, RN, OCN at 802-747-1692

RUTLAND REGIONAL MEDICAL CENTER160 Allen Street, Rutland, VT 05701802.775.7111

© 2020 Rutland Medical Center